Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. mirasys

MIRASYS

The diagnostic potential of miRNAs for early diagnosis of Systemic Sclerosis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MIRASYS project word cloud

Explore the words cloud of the MIRASYS project. It provides you a very rough idea of what is the project "MIRASYS" about.

full    plan    ssc    accelerate    assay    life    sclerosis    company    monitoring    complications    found    subjects    thoroughly    proprietary    breakthrough    disease    manifestations    setting    systemic    detection    progression    microrna    boundaries    commercial    professionals    off    investors    profiles    prior    demonstrated    ip    incorporate    characterised    fibrosis    science    stage    consolidated    panel    diagnosis    presented    burden    onset    internal    business    commercialise    market    elevated    unknown    actionable    formulate    strategy    diagnostics    landscape    autoimmune    feasibility    skin    worldwide    biomarkers    analysed    commercialisation    models    strategic    patients    prognostic    clinical    team    freedom    diagnostic    mirnas    expression    connective    impossible    validate    160    grant    approximately    combination    consists    position    symptoms    disorder    mirasys    designed    precede    organs    mirna    correlates    spin    positively    potent    tissue    erc    threatening    poc    operate   

Project "MIRASYS" data sheet

The following table provides information about the project.

Coordinator		 UNIVERSITAIR MEDISCH CENTRUM UTRECHT 

Organization address
address: HEIDELBERGLAAN 100
city: UTRECHT
postcode: 3584 CX
website: www.umcutrecht.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Netherlands [NL]
 Total cost 149˙190 €
 EC max contribution 149˙190 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2015-PoC
 Funding Scheme ERC-POC
 Starting year 2016
 Duration (year-month-day) from 2016-01-01   to  2017-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITAIR MEDISCH CENTRUM UTRECHT NL (UTRECHT) coordinator 149˙190.00

Map

 Project objective

Systemic sclerosis (SSc) is a life-threatening autoimmune connective tissue disorder of unknown cause, characterised by fibrosis of the skin and internal organs. SSc affects approximately 160.000 patients worldwide and is associated with life-long burden of disease. Early detection of SSc is currently impossible as diagnosis is typically based on a combination of late-stage clinical symptoms. Current diagnostics, however, are based on late clinical manifestations. There is a need for actionable biomarkers for early-stage diagnosis and disease monitoring.

Based on proprietary ERC research specific microRNA (miRNA) profiles were found that positively correlates with clinical progression and complications of SSc. Its expression was elevated in subjects who demonstrated symptoms that can precede SSc onset by years. These findings provide strong support for the prognostic and diagnostic properties of the miRNA panel in SSc.

MIRASYS has been designed to accelerate the commercialisation of a panel of highly potent miRNAs that have breakthrough diagnostic potential in SSc. MIRASYS will be used to validate these findings by setting miRNA expression level boundaries for SSc development and to incorporate these in a diagnostic assay. MIRASYS will also assess the commercial feasibility of setting-up a dedicated spin-off company to commercialise the technology. The team has analysed the IP landscape for similar approaches for SSc and no prior art on the specific miRNAs was found. In the MIRASYS ERC PoC Grant, the team will further investigate the IP position and formulate a strong IP strategy including the steps towards full Freedom to Operate.

The MIRASYS team consists of experienced science and business professionals. The team has developed several business models which need to be assessed thoroughly through in-depth market research. The results need to be consolidated into a strong business plan that will be presented to investors and strategic investors.

 Publications

year authors and title journal last update
List of publications.
2017 Marzia Rossato, Alsya J. Affandi, Soley Thordardottir, Catharina G. K. Wichers, Marta Cossu, Jasper C. A. Broen, Frederique M. Moret, Lara Bossini-Castillo, Eleni Chouri, Lenny van Bon, Femke Wolters, Wioleta Marut, Maarten van der Kroef, Sandra Silva-Cardoso, Cornelis P. J. Bekker, Harry Dolstra, Jacob M. van Laar, Javier Martin, Joel A. G. van Roon, Kris A. Reedquist, Lorenzo Beretta, Timothy R.
Association of MicroRNA-618 Expression With Altered Frequency and Activation of Plasmacytoid Dendritic Cells in Patients With Systemic Sclerosis
published pages: 1891-1902, ISSN: 2326-5191, DOI: 10.1002/art.40163 		Arthritis & Rheumatology 69/9 2019-07-26

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MIRASYS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MIRASYS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

CITISENSE (2019)

Evolving communication systems in response to altered sensory environments

Read More  

Mu-MASS (2019)

Muonium Laser Spectroscopy

Read More  

iNANOVAC4CANCER (2019)

BIOHYBRID AND BIODEGRADABLE NANOVACCINES FOR CANCER IMMUNOTHERAPY

Read More